Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 15/20 | 0.44 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630631 | 1.00 | FOLH1 (0.54) | FOLH1BACE1CTSDBACE2CPB2 | |
| SCHEMBL29630586 | 0.94 | CPB2 (0.47) | FOLH1CPB2NMT2NMT1 | |
| SCHEMBL11087895 | 0.93 | FOLH1 (0.56) | FOLH1BACE1CTSDBACE2CPB2 | |
| SCHEMBL29458355 | 0.93 | BACE1 (0.46) | FOLH1BACE1CTSDBACE2NMT2 | |
| SCHEMBL11086609 | 0.92 | FOLH1 (0.50) | FOLH1BACE1CTSDBACE2NMT2 | |
| SCHEMBL29392074 | 0.92 | FOLH1 (0.46) | FOLH1CPB2NMT2NMT1 | |
| SCHEMBL29630401 | 0.92 | BACE1 (0.48) | BACE1CTSDBACE2 | |
| SCHEMBL30099641 | 0.91 | FOLH1 (0.65) | FOLH1CPB2NMT2NMT1 | |
| SCHEMBL30099510 | 0.91 | FOLH1 (0.65) | FOLH1CPB2NMT2NMT1 | |
| SCHEMBL29715043 | 0.91 | FOLH1 (0.49) | FOLH1BACE1CTSDBACE2NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| EP-4345104-A1 | METHOD FOR PREPARING LIRAGLUTIDE | Bachem Holding AG (CH) | 2024-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | FOLH1 68/4885BACE1 146/4885CTSD 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.